2019 ACR/AF指南:幼年特发性关节炎相关葡萄膜炎的筛查、监测与治疗
该指南由儿科风湿病学家、葡萄膜炎专家、患者代表和方法学家共同制定,采用GRADE方法系统评价文献并通过共识形成推荐。推荐对JIA患儿定期眼科筛查,频率基于个体危险因素;葡萄膜炎患儿定期眼科监测,间隔基于眼部检查结果和治疗方案;局部糖皮质激素作为初始治疗,需要全身治疗时推荐甲氨蝶呤、阿达木单抗和英夫利西单抗。
要点
- JIA患儿应定期眼科筛查,频率基于个体危险因素。
- 葡萄膜炎患儿应定期眼科监测,间隔基于眼部检查结果和治疗方案。
- 局部糖皮质激素为初始治疗,全身治疗推荐甲氨蝶呤、阿达木单抗和英夫利西单抗。
核心结论
- 该指南为JIA相关葡萄膜炎患儿的筛查、监测和管理提供了基于GRADE方法和共识过程的推荐。
研究设计与样本
- 由儿科风湿病学家、葡萄膜炎眼科专家、患者代表和方法学家制定关键临床问题,系统文献评价采用GRADE方法,共识过程形成推荐并分级为有条件或强推荐。
主要发现
- 由于缺乏高质量证据,推荐基于现有证据和共识专家意见制定。
- 推荐对JIA患儿定期眼科筛查,频率基于个体危险因素。
- 推荐对葡萄膜炎患儿定期眼科监测,间隔基于眼部检查结果和治疗方案。
- 眼科监测推荐为强推荐,主要因监测不频繁可能导致葡萄膜炎的视力威胁并发症。
- 局部糖皮质激素应作为初始治疗以控制炎症;需要全身治疗时推荐甲氨蝶呤和TNF抑制剂阿达木单抗、英夫利西单抗。
关键数值与推荐
- 眼科监测推荐为强推荐,主要因监测不频繁可能导致葡萄膜炎的视力威胁并发症。
- 局部糖皮质激素应作为初始治疗以控制炎症。
- 需要全身治疗时推荐甲氨蝶呤和单克隆抗体TNF抑制剂阿达木单抗、英夫利西单抗。
- 对于持续存在视力丧失风险的患儿,推荐及时加用非生物制剂和生物制剂以维持葡萄膜炎控制。
临床怎么用
- 临床医生应基于个体危险因素对JIA患儿进行定期眼科筛查。
- 对葡萄膜炎患儿根据眼部检查结果和治疗方案定期进行眼科监测。
- 初始治疗使用局部糖皮质激素控制炎症,需要全身治疗时选用甲氨蝶呤、阿达木单抗或英夫利西单抗。
- 对持续视力丧失风险的患儿及时加用非生物制剂和生物制剂。
局限性
- 由于缺乏高质量证据,推荐基于现有证据和共识专家意见制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA). METHODS: Pediatric rheumatologists, ophthalmologists with expertise in uveitis, patient representatives, and methodologists generated key clinical questions to be addressed by this guideline. This was followed by a systematic literature review and rating of the available evidence according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. A group consensus process was used to compose the final recommendations and grade their strength as conditional or strong. RESULTS: Due to a lack of literature with good quality of evidence, recommendations were formulated on the basis of available evidence and a consensus expert opinion. Regular ophthalmic screening of children with JIA is recommended because of the risk of uveitis, and the frequency of screening should be based on individual risk factors. Regular ophthalmic monitoring of children with uveitis is recommended, and intervals should be based on ocular examination findings and treatment regimen. Ophthalmic monitoring recommendations were strong primarily because of concerns of vision-threatening complications of uveitis with infrequent monitoring. Topical glucocorticoids should be used as initial treatment to achieve control of inflammation. Methotrexate and the monoclonal antibody tumor necrosis factor inhibitors adalimumab and infliximab are recommended when systemic treatment is needed for the management of uveitis. The timely addition of nonbiologic and biologic drugs is recommended to maintain uveitis control in children who are at continued risk of vision loss. CONCLUSION: This guideline provides direction for clinicians and patients/parents making decisions on the screening, monitoring, and management of children with JIA and uveitis, using GRADE methodology and informed by a consensus process with input from rheumatology and ophthalmology experts, current literature, and patient/parent preferences and values.
引用
- Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019. PMID: 31021511. doi:10.1002/art.40885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。